Phase 4
Completed N=1
An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia
Source: ClinicalTrials.gov NCT01716221 ↗Enrolled (actual)
1
Serious AEs
0.0%
Results posted
Sep 2016
Primary outcomePrimary: International Cooperative Ataxia Rating Scale (ICARS) — 39; 30; 47; 46 units
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of this study is to document the clinical effects of bupropion and citalopram in a single subject with Friedreich Ataxia.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY International Cooperative Ataxia Rating Scale (ICARS) |
39; 30; 47; 46; 42 | — |
| PRIMARY Friedreich Ataxia Rating Scale (FARS) |
43; 41; 47; 42; 45 | — |
| SECONDARY Comparison of FARS and ICARS |
1; -6; 1; 12; 6 | — |
Eligibility Criteria
Inclusion Criteria
- Friedreich Ataxia
Exclusion Criteria
- Unable to provide Informed Consent
Data sourced from ClinicalTrials.gov (NCT01716221). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.